Snapshot from Jul 07, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / United States — Centers for Disease Control and Prevention / Mapp Biopharmaceutical

United States — Centers for Disease Control and Prevention & Mapp Biopharmaceutical

1 shared events · Importance 4 · Last updated Jul 04, 2026

Importance
4
Shared Events
1
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
Shared Events (1)
39
Tech
WHO Lists Bundibugyo Ebola Test
United States — Centers for Disease Control and Prevention: The United States — Centers for Disease Control and Prevention (Africa CDC) has supported the expansion of laboratory testing capacity in affected provinces, working with the World Health Organization to combat the Bundibugyo ebolavirus outbreak.
Mapp Biopharmaceutical: Mapp Biopharmaceutical's experimental MBP134 antibody is being evaluated in a treatment trial for the Bundibugyo Ebola outbreak in the Democratic Republic of the Congo, either as a standalone treatment or in combination with Gilead Sciences' remdesivir.
Jul 02, 2026 · 8 articles
NEWSDESK
Explore this relationship live

Track how United States — Centers for Disease Control and Prevention and Mapp Biopharmaceutical interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.